Trevi Therapeutics (TRVI) to Release Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.1095) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, analysts expect Trevi Therapeutics to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trevi Therapeutics Price Performance

NASDAQ:TRVI opened at $18.33 on Tuesday. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -57.28 and a beta of 1.03. The company has a 50 day moving average price of $16.63 and a 200-day moving average price of $13.81. Trevi Therapeutics has a 1-year low of $6.55 and a 1-year high of $20.22.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Alliancebernstein L.P. raised its holdings in Trevi Therapeutics by 19,064.5% in the 2nd quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company’s stock valued at $23,419,000 after acquiring an additional 4,259,015 shares during the last quarter. Rubric Capital Management LP boosted its holdings in shares of Trevi Therapeutics by 88.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after purchasing an additional 3,993,325 shares during the last quarter. Viking Global Investors LP boosted its holdings in shares of Trevi Therapeutics by 232.4% during the 3rd quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after purchasing an additional 3,585,875 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Trevi Therapeutics by 1,792.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,253,888 shares of the company’s stock worth $29,773,000 after purchasing an additional 3,081,906 shares during the last quarter. Finally, Marshall Wace LLP grew its position in shares of Trevi Therapeutics by 95.4% in the third quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock valued at $44,302,000 after purchasing an additional 2,363,835 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TRVI shares. Wall Street Zen lowered shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. HC Wainwright upped their price objective on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. Finally, Stifel Nicolaus set a $30.00 price target on Trevi Therapeutics in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $24.91.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.